These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31147529)

  • 21. Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer.
    Ang L; Guo L; Wang J; Huang J; Lou X; Zhao M
    Cancer Lett; 2020 Jun; 479():42-53. PubMed ID: 32200038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling.
    Li B; Huang L; Ruan J
    Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
    Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
    Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
    J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition.
    Wang H; Sang M; Geng C; Liu F; Gu L; Shan B
    Neoplasma; 2016; 63(1):44-56. PubMed ID: 26639233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model.
    Guo Y; Fan Y; Pei X
    Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
    Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
    Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression.
    Wang Y; Xu X; Zhao P; Tong B; Wei Z; Dai Y
    Oncotarget; 2016 Apr; 7(17):23684-99. PubMed ID: 27008697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
    Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
    Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epithelial-mesenchymal transition induced PAI-1 is associated with prognosis of triple-negative breast cancer patients.
    Xu J; Zhang W; Tang L; Chen W; Guan X
    Gene; 2018 Sep; 670():7-14. PubMed ID: 29802992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
    Yang M; Teng W; Qu Y; Wang H; Yuan Q
    Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
    Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer.
    Liu S; Wang Z; Liu Z; Shi S; Zhang Z; Zhang J; Lin H
    J Mol Cell Biol; 2018 Aug; 10(4):302-315. PubMed ID: 30053090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
    Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
    Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
    Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
    Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.